We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 6.00 | 2.83% | 218.00 | 27,200 | 16:35:05 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 218.00 | 220.00 | 222.00 | 210.00 | 217.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 838M | USD 100.78M | USD - | - | 1.85B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:05 | UT | 5,674 | 218.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/1/2025 | 09:00 | UK RNS | Hutchmed (China) Limited Overseas Regulatory Announcement |
| 14/1/2025 | 12:07 | ALNC |  IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China |
| 14/1/2025 | 07:00 | UK RNS | Hutchmed (China) Limited Full Approval for ORPATHYS in China |
| 02/1/2025 | 10:46 | ALNC | Hutchmed China disposes of 45% stake in Shanghai joint venture |
| 02/1/2025 | 07:01 | UK RNS | Hutchmed (China) Limited China NDA Acceptance for ORPATHYS and TAGRISSO |
| 02/1/2025 | 07:00 | UK RNS | Hutchmed (China) Limited Overseas Regulatory Announcement |
| 02/1/2025 | 07:00 | UK RNS | Hutchmed (China) Limited US$608m Divestment of Non-Core Joint Venture |
| 31/12/2024 | 08:30 | UK RNS | Hutchmed (China) Limited Appointment of Joint Corporate Broker |
| 30/12/2024 | 08:30 | UK RNS | Hutchmed (China) Limited Blocklisting Six Monthly Return |
| 13/12/2024 | 10:04 | ALNC | IN BRIEF: Hutchmed to get Takeda milestone payment |
Hutchmed (china) (HCM) Share Charts1 Year Hutchmed (china) Chart |
|
1 Month Hutchmed (china) Chart |
Intraday Hutchmed (china) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/2/2025 | 16:13 | (Chi-Med)Hutchinson China Meditech Limited | 4,115 |
| 25/3/2022 | 17:25 | Hutchison Chi-Med (HCM) One to Watch | 3 |
| 23/7/2018 | 09:55 | Hutchison Chi-Med (HCM) One to Watch on Monday | 1 |
| 13/6/2017 | 06:54 | Hutchison China Meditech- CHARTS AND DISCUSSION | 74 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-02-14 16:35:05 | 218.00 | 5,674 | 12,369.32 | UT |
| 2025-02-14 16:19:30 | 220.00 | 104 | 228.80 | AT |
| 2025-02-14 16:16:12 | 221.94 | 5,287 | 11,733.89 | O |
| 2025-02-14 16:04:52 | 222.00 | 11 | 24.42 | AT |
| 2025-02-14 16:04:52 | 222.00 | 8 | 17.76 | AT |
| Top Posts |
|---|
Posted at 15/2/2025 08:20 by Hutchmed (china) Daily Update Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 212p.Hutchmed (china) currently has 871,601,095 shares in issue. The market capitalisation of Hutchmed (china) is -. This morning HCM shares opened at 217p |
Posted at 13/2/2025 09:22 by 1jat Mcmather - sentiment towards HK/China is poor in the west. No doubt HK/China is sceptical of the value of western operations represented in HK companies. So CKHH gets a double negative view. CKHH as a conglomerate trades at a hefty discount - if you add the market value of its listed subs you get the mcap of the parent. One might think the logical answer is a break up and realisation of the value of the assets……There is little synergy within the CK group of companies for Hutchmed to exploit and it seems to have been on its own for a while with CKHH selling down to under 40%. Hutchmed seems to be inhabiting a nether world where it has grown into a commercial organisation, but its larger competitors are interested in smaller bolt on acquisitions. Eventually the mid sized companies will need to huddle together to avoid being preyed upon or accept they will be only a bit part player in the background. The Sovlep manufacturing issue is just the latest in a steady flow of mis-steps. I think it is time for Victor to make a trade in HCM. |
Posted at 12/2/2025 20:28 by mcmather Double yer money from here..."Feb. 11, 2025, 09:25 AM BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target" |
Posted at 28/1/2025 14:54 by the grumpy old men HUTCHMED Announces Delay in Circular Dispatch for Major TransactionTipRanks UK Auto-Generated Newsdesk Jan 28, 2025, 10:02 AM Story Highlights HUTCHMED plans to divest a 45% stake in Shanghai Hutchison Pharmaceuticals. The dispatch of transaction details is postponed until February 28, 2025. HUTCHMED (China) Limited ( HK:0013 -1.42% ▼ ) just unveiled an announcement. HUTCHMED (China) Limited announced a major transaction involving the disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited, valued at US$608 million. The dispatch of the circular detailing this transaction has been delayed until February 28, 2025, due to additional time needed by GP Health Service Capital to finalize details. This delay is attributed to the Chinese New Year holidays, and stakeholders are advised to exercise caution regarding the deal’s completion, as it is contingent on the satisfaction of certain conditions. HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company dedicated to the discovery and global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought its first three cancer medicines to market in China, with one also approved in the US, Europe, and Japan. YTD Price Performance: -6.81% Average Trading Volume: 55,198 Technical Sentiment Consensus Rating: Buy Current Market Cap: £1.88B TipRanks’ Stock Analysis page. |
Posted at 16/1/2025 15:27 by mcmather Last hour:"Innovent Biologics ( HK:1801 -10.31% ▼ ) has issued an announcement. Innovent Biologics has reported unusual price and trading volume movements in its shares but confirmed no changes in its business operations or any undisclosed information". |
Posted at 14/1/2025 08:38 by waldron Press ReleaseHUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - Indication expands to include treatment-naïve patients - - The 2021 conditional approval in previously treated patients converted to full approval - Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alteration. The NMPA has also converted the prior conditional approval of ORPATHYS® in the previously treated patient population to full approval. The new label indication for ORPATHYS® will now include both treatment-naïve and previously treated patients in China. |
Posted at 12/12/2024 07:44 by lauders Good news again. Will it have any effect on the share price?Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR |
Posted at 17/10/2024 13:32 by 1jat Arguably both cash flow + and - lead to M&A - one as the major party and one as the minor party.There are a lot of biotechs in China and there are significant efficiencies possible across pipeline assets, sales and general administration. New money is hard to raise but mergers are likely to be encouraged by the mainland to build some national champions (globally China cos are not in the big pharma league - that should change). If CKHH is willing to back HCM issuing new equity or taking on some debt, then it should be possible for HCM to take the lead on some M&A deals and grow inorganically - that is how big Pharma got to be big rather than organic growth. Pre-commercial deals - will come with more uncertainty but the target will bring some cash and R&D capabilities. The main economies will come from pushing more volume through the factory and sales channels when the acquired products are approved. Commercial stage deals - Should generate value for both shareholders due to the large synergies…..ba I dont think HCM has the management to do a significant merger at the moment, so if they are to be on the front foot I would expect a new CEO and a strategy director to be appointed first. |
Posted at 16/10/2024 12:18 by dbadvn Won’t affect the share price. Market expects only positive clinical results , only reacts to the negative.It’s all about getting to cash flow positive. No more free money . Cash flow positive means survival and further growth. Not cash flow positive means takeover or merger. We will know which in the next 12 months or so. |
Posted at 12/7/2024 06:35 by 1jat It seems that Goldman is in at CKHH and its reviews are proving a little leaky,Two stories in two days about the European Three mobile telecoms businesses and a second about CK Infrastructure. When they get to HCM it will be no surprise if they suggest M&A with other China biotech (I would not expect HCM to be the buyer as that would not generate immediate gains for CKHH). They should be having these discussions about reaising SH value from time to time. IMO CKHH has incubated HCM and may decide it does not have the resources/appetite to take it much further or the ability as a Board to oversee this specialist investment and therefore seeks to dilute its ownership. If they can get a proposal above hk$50 they will be obliged to seriously consider it. CK deals have often involved a mix of cash and listed shares followed by sell downs (eg recent mobile mast deal in Europe). No certainty of a deal emerging, but I feel there is change coming at CKHH and HCM may not be untouched by it. |
Posted at 14/11/2022 06:58 by lauders Nearly +20% in HK now! Come on HCM share price at least match that! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
